Calliditas Therapeutics Announces Full FDA Approval of Tarpeyo, the Only FDA-Approved Treatment for IgA Nephropathy to Significantly Reduce the Loss of Kidney Function

December 20, 2023 Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to reduce...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news